Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Total Liabilities : ¥1,265 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zhejiang AngliKang Pharmaceutical Co Total Liabilities?

Zhejiang AngliKang Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,265 Mil.

Zhejiang AngliKang Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 (¥1,395.75 Mil) to Dec. 2023 (¥1,187.72 Mil) but then increased from Dec. 2023 (¥1,187.72 Mil) to Mar. 2024 (¥1,264.98 Mil).

Zhejiang AngliKang Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥608.64 Mil) to Dec. 2022 (¥949.93 Mil) and increased from Dec. 2022 (¥949.93 Mil) to Dec. 2023 (¥1,187.72 Mil).

Zhejiang AngliKang Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Zhejiang AngliKang Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang AngliKang Pharmaceutical Co Total Liabilities Chart

Zhejiang AngliKang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

368.51

562.78

608.64

949.93

1,187.72

Zhejiang AngliKang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,087.17	1,135.53	1,395.75	1,187.72	1,264.98

Zhejiang AngliKang Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zhejiang AngliKang Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	731.971	+	(423.95	+	31.8
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,188

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3019.991	-	1832.27
	=	1,188

Zhejiang AngliKang Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	864.059	+	(368.95	+	31.974
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,265

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3133.172	-	1868.189
	=	1,265

Zhejiang AngliKang Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zhejiang AngliKang Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang AngliKang Pharmaceutical Co Ltd (SZSE:002940) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No. 1000, North Luzhou Avenue, Zhejiang Province, Quzhou, CHN, 312400

Website

http://www.alkpharm.com

Zhejiang AngliKang Pharmaceutical Co Ltd is engaged in the manufacturing and sale of pharmaceutical materials, pharmaceutic preparations, and medical empty capsules. The main products offered by the group are cephalosporins antibacterial, angiocarpy drugs and gastrointestinal tract drugs. Geographically, the activities are carried out through Shengzhou, China.

Executives

Pan Xiao Yun	Supervisors
Ye Shu Xiang	Director
Yang Guo Dong	Executives
Xu Ai Fang	Supervisors
Wu Zhe Hua	Director

Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Headlines

No Headlines